Laekna, Inc. (Laekna) has issued a positive profit alert for the six months ended 30 June 2026, indicating a sharp turnaround in its interim financial performance.

Revenue Surge • Management expects first-half revenue to reach RMB145.00 million–RMB155.00 million, compared with zero revenue in the corresponding period of 2025. • The uptick stems primarily from licence income linked to two exclusive agreements: one with Vasque Bio, Inc. for LAE118 and another with Qilu Pharmaceutical Company Limited for LAE002 (afuresertib).

Substantial Loss Reduction • Consolidated net loss is projected at no more than RMB5.00 million, a 96% improvement versus the RMB130.00 million loss reported a year earlier.

Reporting Timeline and Audit Status • Figures are based on unaudited management accounts and may be subject to adjustments. • Detailed interim results are scheduled for release on 25 August 2026. • The board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.